13 research outputs found
Changes in NLR and PSA response rate at 12weeks.
<p>Changes in NLR and PSA response rate at 12weeks.</p
Overall survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
<p>Overall survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.</p
Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
<p>Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.</p
Forest plot for progression-free survival.
<p>Forest plot for progression-free survival.</p
Overall survival in the entire study population according to Memorial Sloan Kettering Cancer Center prognostic risk score.
<p>Overall survival in the entire study population according to Memorial Sloan Kettering Cancer Center prognostic risk score.</p
Overall survival calculated from PM manifestation to death.
<p>Overall survival calculated from PM manifestation to death.</p
Outcome according to MSKCC prognostic group for patients who received only TTs and for those who received pancreatic local treatment (surgery or local radiation therapy).
<p>Outcome according to MSKCC prognostic group for patients who received only TTs and for those who received pancreatic local treatment (surgery or local radiation therapy).</p
Overall survival for patients who underwent pancreatic local treatment (surgery or radiation therapy) and in those who received TTs only.
<p>Overall survival for patients who underwent pancreatic local treatment (surgery or radiation therapy) and in those who received TTs only.</p